|
WO1996024358A1
(en)
*
|
1995-02-10 |
1996-08-15 |
G.D. Searle & Co. |
Use of low dose amount of spironolactone for treatment of cardiovascular disease
|
|
AR030414A1
(es)
*
|
2000-04-03 |
2003-08-20 |
Astrazeneca Ab |
Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
|
|
SE0002354D0
(sv)
*
|
2000-06-22 |
2000-06-22 |
Astrazeneca Ab |
New formulation
|
|
FI20010233A0
(fi)
*
|
2001-02-08 |
2001-02-08 |
Orion Corp |
Menetelmä sydämen vajaatoiminnan hoitoon
|
|
FI20011464A0
(fi)
|
2001-07-04 |
2001-07-04 |
Orion Corp |
Yhdistelmäterapia sydämen vajaatoiminnan hoitoon
|
|
US7020521B1
(en)
|
2002-11-08 |
2006-03-28 |
Pacesetter, Inc. |
Methods and apparatus for detecting and/or monitoring heart failure
|
|
KR20120008093A
(ko)
|
2003-11-17 |
2012-01-25 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
|
EP1699436A2
(en)
*
|
2003-12-12 |
2006-09-13 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
|
|
JP2007530563A
(ja)
*
|
2004-03-22 |
2007-11-01 |
ミオゲン インコーポレイティッド |
（ｓ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
|
|
WO2005092333A1
(en)
*
|
2004-03-22 |
2005-10-06 |
Myogen, Inc. |
(r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
|
|
WO2006007213A1
(en)
*
|
2004-06-23 |
2006-01-19 |
Myogen, Inc. |
Enoximone formulations and their use in the treatment of pde-iii mediated diseases
|
|
WO2006031955A2
(en)
*
|
2004-09-14 |
2006-03-23 |
The Regents Of The University Of Colorado, A Body Corporate |
Method for treatment with bucindolol based on genetic targeting
|
|
CA2610022A1
(en)
|
2005-06-06 |
2006-12-14 |
Georgetown University |
Compositions and methods for lipo modeling
|
|
WO2007014033A2
(en)
*
|
2005-07-22 |
2007-02-01 |
The Regents Of The University Of Colorado, A Body Corporate |
Inhibition of extracellular signal-regulated kinase 1/2 as a treatment for cardiac hypertrophy and heart failure
|
|
WO2011032088A1
(en)
|
2009-09-11 |
2011-03-17 |
Arca Biopharma, Inc. |
Polymorphisms in the pde3a gene
|
|
BR112019013702A2
(pt)
*
|
2017-01-03 |
2020-03-03 |
Cardioxyl Pharmaceuticals, Inc. |
Método de administração de compostos doadores de nitroxila
|
|
IL283725B2
(en)
|
2017-06-20 |
2024-04-01 |
Imbria Pharmaceuticals Inc |
Compositions and methods for increasing efficiency of cardiac metabolism
|
|
WO2020081361A1
(en)
|
2018-10-17 |
2020-04-23 |
Imbria Pharmaceuticals, Inc. |
Methods of treating rheumatic diseases using trimetazidine-based compounds
|
|
WO2021225950A1
(en)
*
|
2020-05-04 |
2021-11-11 |
Imbria Pharmaceuticals, Inc. |
Dosing methods for treatment of cardiovascular conditions
|
|
US11530184B2
(en)
|
2020-06-30 |
2022-12-20 |
Imbria Pharmaceuticals, Inc. |
Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11780811B2
(en)
|
2020-06-30 |
2023-10-10 |
Imbria Pharmaceuticals, Inc. |
Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
|
|
US11883396B2
(en)
|
2021-05-03 |
2024-01-30 |
Imbria Pharmaceuticals, Inc. |
Methods of treating kidney conditions using modified forms of trimetazidine
|